Follow-up

Previously untreated, unresectable mCRC

XELOX or mFOLFOX6 + Bev

Phase A treatment ¹

PD1

8-9 weekly assessments

Phase B treatment ²

Bev + FOLFIRI

PD2

8 weekly assessments

Follow-up

¹ If oxaliplatin must be discontinued, fluoropyrimidine + bevacizumab should be continued until 1st disease progression

² If irinotecan must be discontinued, fluoropyrimidine + bevacizumab should be continued until 2nd disease progression